STREAM is the first large-scale, multi-country clinical trial to investigate shortened regimens for multidrugresistant tuberculosis (MDR-TB), and the first phase III trial to test the efficacy and safety of Bedaquiline, a new drug with a novel mechanism of action, within a shortened treatment regimen.
The trial established a Community Engagement (CE) Plan. The CE program was implemented at thirteen research sites within the STREAM trial, in seven countries. This paper sets out a summary of the experiences of CABs in connection with the STREAM clinical trial. It underlines relevant aspects that may be useful when planning and/or engaging communities in research. In conclusion, the experiences gained during STREAM, lead to both growing confidence in CE as a valuable process and community participation in advocacy.
Recent Abstracts
Information About New Federal Regulations for Opioid Treatment Programs (OTPs)
Centering Country Ownership and Leadership: The Data for Health Initiative’s Approach
Mass Media Campaigns
Data for Health: Advancing Gender Equity
The Index of Tobacco Control Sustainability
Index of Tobacco Control Sustainability (ITCS): India Subnational Tobacco Control
Index of Tobacco Control Sustainability (ITCS): Indonesia Subnational Tobacco Control
Considerations for Planning Childhood Blood Lead Surveillance
Air Quality Monitoring Toolkit: Assessing Second-Hand Smoke in Hospitality Venues
Association between high-threshold practices and buprenorphine treatment termination